

Table E-2. Study characteristics for trials comparing antidepressant with placebo

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Suvanto-Luukkonen 2005	Finland	2	149	RCT Plac Compare	3	39	Yes	No/NR
Evans 2005	United States	1	80	RCT Plac Compare	2	12	Yes	No/NR
Kerwin 2007	United States	NR	87	Crossover	2	4	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Kalay 2007	Turkey	NR	50	RCT Plac Compare	2	8		No/NR
Speroff 2008	United States	37	620	RCT Plac Compare	5	12	Yes	No/NR
Soares 2008	Canada	NR	56	RCT Plac Compare	2	6	Yes	No/NR
Archer 2009	United States	32	541	RCT Plac Compare	3	26	Yes	Yes
Archer 2009	United States	34	452	RCT Plac Compare	3	12	Yes	Yes
Kornstein 2010	United States	37	372	RCT Plac Compare	2	8	Yes	Yes
Soares 2010	Multinational	72	461	RCT Active Compare	2	8	Yes	No/NR
Freeman 2011	United States	4	205	RCT Plac Compare	2	8		No/NR
Bouchard 2012	Multinational	38	287	RCT Plac Compare	2	12	Yes	Yes
Pinkerton 2012	United States	122	365	RCT Plac Compare	2	52	Yes	Yes
Simon (Study 2) 2013	United States	Mult i	568	RCT Plac Compare	2	24	Yes	Yes
Pinkerton 2013	United States	122	2118	RCT Plac Compare	2	52	Yes	Yes
Simon (Study 1) 2013	United States	Mult i	606	RCT Plac Compare	2	12	Yes	Yes

(c): data came from posted results on the clinical trial registry; F/U: followup NR: not reported; Plac: placebo; RCT: randomized controlled trial